• Home
  • About us
  • Our Services
  • Products
  • News
  • Contact
  • ES
Menu
  • Home
  • About us
  • Our Services
  • Products
  • News
  • Contact
  • ES
Benzydamine and Cetilpiridinium Lozenges
4 de January de 2023
Hyoscine + Paracetamol film coated tablets
16 de August de 2023
Published by Geiser Pharma on 4 de January de 2023
Categories
  • Geiser Pharma Newsletter
  • News
Tags
Geiser Pharma annual newsletter. A company specialised in the development of value added product. Don't miss out dossiers ready to be license out

Table of contents

CEO INSIGHTS

2022 KEY ACHIEVEMENTS

ELEVATE WITH OUR PRODUCTS

NEW DEVELOPMENTS IN OUR PIPELINE

CEO INSIGHTS

Written by Veronica Madrid

Another year has passed, even more challenging than the previous one, where the Cough & Cold demand of products has significantly increased in an unpredictable economic context that caused unforeseeable pressures on supply chains, impacting our daily costs and regular processes.

More than ever, flexibility has been our key pillar, as day by day we had to redefine our plans and strategy according to our client’s needs in a complex and constantly changing environment.

I would like to take a moment to recognize our team and shareholders for all the accomplishments made during the year, which couldn’t be possible without their commitment, dedication and efforts.

This year we have made significant progress in growing our pipeline with 5 new developments and we are extremely excited to continue our research and innovation to develop future products within 2023.

This year we have also expanded our activity to new territories where Geiser Pharma was not present yet, such as Colombia, China and Vietnam and we have reinforced our expansion plans to Canada and Brazil for 2023.

This could not have been possible without the collaboration and trust of our clients and partners, that has also enabled us to sign 35 new contracts.

On behalf of Geiser’s team and Board of Directors, I sincerely thank you for your continued support despite all the difficulties and I am confident that we will be able to reach our goals and even exceed our challenging expectations for the upcoming exciting years.

2022 Key achievements

Elevate with our products

Doxylamine Succinate

Doxylamine Succinate Tablets

The treatment of occasional insomnia is another of our priorities. This is shown through our two doxylamine’s products, an effective API in reducing the time to sleep onset as well as to increase the depth and duration.


Doxylamine succinate is available in tablets, for the more traditional consumers, as well as in oral powder with strawberry flavour, an easy-to-use pharmaceutical form that does not require water that could differentiate yourself from competitors.

Sin título (430 × 850 px) (13)

Hioscine & Paracetamol

Our extensive experience in the development of pharmaceutical products leads us to cover new therapeutic areas such as women’s health and pain relief. antispasmodic-analgesic coated tablets help to relieve from the pain of stronger abdominal cramps including menstrual cramps and urinary tract spasm.

The 10 mg of Hyoscine-N-butylbromide, an antispasmodic substance that relieves the pain by acting on the muscle, together with analgesic properties of the 500 mg of Paracetamol, allows cramped muscles to relax and simultaneously delivers fast relief from pain.

A product manufactured by a CMO with extensive experience with paracetamol that will be ready to be presented in agencies from the end of 2023.

New products in our pipeline

Flurbiprofen Lozenges
Cherry Flavour

Short-term symptomatic relief of the sore throat in adults and children over the age of 12 years.

AMYL + CDBA SPRAY

Symptomatic relief of mouth and throat infections.

Propolis, Manuka Honey, Vit C, Matricaria, Erysim

Soothe and relieve sore throats.

Ibuprofen Soft Gel capsules

Relieve pain and reduce swelling

Lidocaine Combination Spray
Cherry Flavour

Symptomatic relief of throat infections, including severe sore throats

Join our mailing list!
Share
0
Geiser Pharma
Geiser Pharma

Related posts

10 de October de 2023

Research and Development (R&D) in Value-Added Pharmaceutical Products Award


Read more
22 de March de 2022

Geisoutside: End of the year Newsletter 2021


Read more
29 de March de 2021

Geiser Pharma is visited by Europa Press for being selected as SME of the year of Navarre


Read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Linkedin

Products

  • OTC
  • Medical devices
  • RX

Contact

Polígono Industrial Mutilva

Calle E, nº5

31192 Mutilva (Navarra, Spain)

Teléfono: +34 948 101 943

Fax: +34 948 229 090

geiserpharma@geiserpharma.com

 

Copyright © 2021, Geiser Pharma. All rights reserved - Legal notice, privacy policy and data protection | Cookies policy